Novartis CEO sees no need for big takeover
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Bristol-Myers Squibb (BMY) Granted European Commission Approval Opdivo (Nivolumab)
June 2, 2017 5:06 PM EDTBristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission (EC) has approved Opdivo (nivolumab) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy. Todays decision makes Opdivo the first Immuno-Oncology agent approved in the European Union for... More
Bristol-Myers Squibb (BMY) & Seattle Genetics (SGEN) Announce Expanded Collaboration to Evaluate Combination of Opdivo (Nivolumab) & ADCETRIS (Brentuximab Vedotin) in Phase 3 Clinical Trial
June 2, 2017 6:03 AM EDTBristol-Myers Squibb Company (NYSE: BMY) and Seattle Genetics, Inc. (Nasdaq:... More
